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Abstract
Purpose: Ebola virus (EBOV) is such kind of virus which is responsible for 23,825 cases and 9675 deaths worldwide only
in 2014 and with an average diseases fatality rate between 25 % and 90 %. Although, medical technology has tried to
handle the problems, there is no Food and Drug Administration (FDA)-approved therapeutics or vaccines available for
the prevention, post exposure, or treatment of Ebola virus disease (EVD).
Methods: In the present study, we used the immunoinformatics approach to design a potential epitope-based vaccine
against the RNA-dependent RNA polymerase-L of EBOV. BioEdit v7.2.3 sequence alignment editor, Jalview v2 and CLC
Sequence Viewer v7.0.2 were used for the initial sequence analysis for securing the conservancy from the sequences.
Later the Immune Epitope Database and Analysis Resource (IEDB-AR) was used for the identification of T-cell and
B-cellepitopes associated with type I and II major histocompatibility complex molecules analysis. Finally, the population
coverage analysis was employed.
Results: The core epitope “FRYEFTAPF” was found to be the most potential one, with 100 % conservancy among all the
strains of EBOV. It also interacted with both type I and II major histocompatibility complex molecules and is considered
as nonallergenic in nature. Finally, with impressive cumulative population coverage of 99.87 % for the both MHC-I and
MHC-II class throughout the world population was found for the proposed epitope.
Conclusion: To end, the projected peptide gave us a solid stand to propose for vaccine consideration and that might
be experimented for its potency in eliciting immunity through humoral and cell mediated immune responses in vitro
and in vivo.
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Background
EVD, previously designated as Ebola haemorrhagic
fever, is a fatal disease in humans and other mammals
(monkeys, chimpanzees and gorillas) (Choi and Croyle
2013, Leroy et al. 2004, Sullivan et al. 2000). The fatality
rate of EDV is varied from 25 to 90 % with an average of
about 50 % (Peters and Peters 1999) and it is caused by
a virus of the family Filoviridae, genus Ebolavirus. There
are five separate Ebola virus species have been identified,
four of which are disease causing to humans: Ebola virus
(Zaire ebolavirus); Taï Forest virus (Taï Forest ebolavirus,
formerly Côte d’Ivoire ebolavirus); Sudan virus (Sudan
ebolavirus); and Bundibugyo virus (Bundibugyoebolavirus)
(Hoenen et al. 2012). The fifth one, Reston virus (Reston
ebolavirus), is harmful to nonhuman primates, but not to
humans (Elisha and Adegboro 2014, Geisbert et al. 2009).
Among the recognized species of ebolavirus, the notori-
ously deadly Zaire ebolavirus is responsible for epidemics
which have been taken place mainly in African countries
including Democratic Republic of Congo, Uganda, Sudan,
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the Ivory Coast, and Gabon (Baize et al. 2014, Chowell et
al. 2004, Feldmann et al. 2003, Frieden et al. 2014, Hewlett
and Hewlett 2005, Kuhn et al. 2010, Li and Chen 2014,
Rouquet et al. 2005). This virus is passed on people from
wild animals and through human-to-human contact trans-
mits in the human population. Those are infected with
this virus bear fearsome symptoms, including high fever,
hemoptysis, impaired kidney and liver function and severe
internal bleeding (Gatherer 2014, Goeijenbier et al. 2014,
Keiser et al. 2004, Peters and Peters 1999). In the fall of
2014 the Ebola virus gained widespread attention when in
West Africa the largest outbreak has been reported in
history.
The EBOV genome is a single-stranded, negative-sense,
non-segmented RNA approximately 19 kb long. It codes
for seven tandemly arranged viral genes which order is 3′
leader- NP (nucleoprotein) - VP35 (virion protein 35)-
VP40- GP (glycoprotein)-VP30-VP24- L (RNA-dependent
RNA polymerase)-trailer −5′. Transcription and transla-
tion of this viral genome result in the synthesis of seven
structural proteins and a single non-structural, secreted
glycoprotein (Feldmann et al. 1999). Three of the struc-
tural proteins are membrane-associated proteins; GP is a
type I transmembrane protein, while VP24 and VP40 are
placed on the inner surface of the membrane. The
remaining four, NP, VP30 (transcription factor), VP35
(polymerase cofactor), and L (RNA-dependent RNA poly-
merase), are essential to viral genomic RNA to form the
ribonucleoprotein complex. These proteins have been
shown to be necessary and sufficient for EBOV transcrip-
tion and replication (Crary et al. 2003, Feldmann et al.
2001, Mühlberger et al. 1998; 1999, Takada et al. 1997).
To date, information regarding the processing, struc-
ture and functions of Ebola virus (EBOV) protein L
(EBOL) demonstrates that it is an RNA-dependent RNA
polymerase, with the assistance of VP35. It also shows
mRNA (guanine-N (7)-)-methyltransferase, mRNA gua-
nylyltransferase and poly (A) synthetase activities which
are essential for the replication and transcription of
EBOV (Poch et al. 1990). The viral mRNA guanylyl-
transferase serves either as transcriptase or as replicase.
The transcriptase synthesizes subgenomic RNAs, assures
their capping and polyadenylation. The transcriptase stut-
ters on a specific sequence, leads to a co-transcriptional
editing of the glycoprotein (GP) mRNA. In replicase mode,
the polymerase replicates the viral genome without recog-
nizing the transcriptional signals. These reports suggest
that EBOL is an important cellular component for the
transcription and replication of the EBOV genome and, as
such, plays a key role in the EBOV life cycle.
Due to the emergence of Ebola virus outbreak, there is
an immediate need to determine novel therapeutic targets
against this pathogen. The identification of specific epi-
topes derived from infectious pathogens has significantly
advanced the development of epitope-based vaccines
(EVs). Bettered understanding of the molecular basis of
antigen recognition and HLA binding motifs has resulted
in the advancement of rationally designed vaccines depend
on algorithms predicting the peptide’s binding to human
HLA. In comparison to the conventional vaccines, peptide
or epitope based vaccines are easy to develop, chemical
stable, more specific, and free of any infectious or onco-
genic potential hazard (Holland and Domingo 1998, Sette
et al. 2002). Though EVs have varied advantages, the wet
lab based discovery of candidate epitopes is expensive and
time consuming. Furthermore, for the final selection of
epitopes various immunological requirements are needed
to be considered. As a result computational methods, an
alternative in silico approaches (Germain 1994) have re-
cently been attracting growing interest of the researchers
for predicting epitopes with reduced cost and time. The
application of bioinformatics in immunology is termed as
immunoinformatics. Currently, numerous immunoinfor-
matics tools are available for identifying B and T cell epi-
topes and human leukocyte antigen (HLA) ligands
(Petrovsky and Brusic 2002, Poland et al. 2009, Sette and
Fikes 2003) with high sensitivity and specificity. The
‘immunoinformatics’ approach has already proven its
potency in the case of human immunodeficiency virus
(Wilson et al. 2003), multiple sclerosis (Bourdette et al.
2005), tuberculosis (Robinson and Amara 2005) and
malaria (López et al. 2001) with desired results. In the
present study, we have followed immunoinformatics
approaches for designing potential conserved epitope
candidate for the utility of vaccine development against
the deadly Ebola virus, with an expectation of further
wet lab validation.
Methods
Sequence retrieval and conserved region identification
The protein sequences of the RNA-dependent RNA
polymerase-L (Volchkov et al. 1999) of the EBOV were
retrieved from the UniProtKB (Apweiler et al. 2004)
database in the FASTA format. BioEdit v7.2.3 sequence
alignment editor (Apweiler et al. 2004) was used for the
identification of the conserved region among the se-
quences through multiple-sequence alignment (MSA)
with ClustalW (Hall 1999). Finally, Jalview v2 tool
(Thompson et al. 1994) was used to retrieve the align-
ment and the CLC Sequence Viewer v7.0.2 (http://
www.clcbio.com) was used for analysis of the divergence
among the different strains of the EBOV.
Antigenicity determination of the conserved peptides
VaxiJen v2. 0, a Web-based server (Waterhouse et al.
2009, Doytchinova and Flower 2007) was used for the
determination of the antigenicity of the conserved
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sequences. Herein, we used the default parameters for
the prediction, with a threshold value of 0.4.
T-cell epitope prediction
For this study, two online servers were used. Firstly,
the NetCTL v1.2 server (Larsen et al. 2007) was used
for predicting potential cytotoxic T lymphocyte (CTL)
epitopes from the conserved peptides. Here for pre-
dicting the epitopes, we used a combined algorithm
including major histocompatibility complex class I
(MHC-I) binding, transporter of antigenic peptide
(TAP) transport efficiency, and proteasomal C terminal
cleavage prediction. Depending on the score, the best
candidates were picked for further investigation. The
epitope prediction was confined to 12 MHC-I super-
types. MHC-I binding and proteasomal cleavage were
carried out through artificial neural networks and the
weight matrix was used to estimate the TAP transport
efficiency. The threshold value for epitope identifi-
cation was set at 0.5 for maintaining sensitivity and
specificity of 0.89 and 0.94, respectively during the
analysis. This would support to assess the findings
more decisively by developing more epitopes. Finally,
for confirming the prediction with default parameters,
CTLPred (Bhasin and Raghava 2004) was employed
additionally.
MHC-I and MHC-II restriction analysis
Furthermore, from the Immune Epitope Database and
Analysis Resource (IEDB-AR), T Cell Epitope Predic-
tion Tools was implied for the identification of MHC-I
(Hoof et al. 2009, Nielsen et al. 2007) and MHC-II
(Wang et al. 2008; 2010) binding of the peptide. In
order to calculate the half-maximal inhibitory concen-
tration (IC50) values required for peptide binding to
MHC-I molecules, Stabilized Matrix Method (Peters
and Sette 2005) was applied with a preset 9.0-mer
epitope.
In case of MHC-II binding analysis, the IEDB-recom-
mended method was used for the specific HLA-DQ, HLA-
DP, and HLA-DR loci. Herein, specific peptides were used
to predict the MHC-II interaction on the basis of MHC-I
analysis and antigenic conservancy.
Prediction of population coverage
Population coverage for epitope was assessed by the
IEDB population coverage calculation tool (Bui et al.
2006). Here we used the allelic frequency of the
interacting HLA alleles for the prediction of the
population coverage for the corresponding epitope.
B-cell epitope prediction
Linear B cell epitopes are of different lengths of pep-
tides from 2 to 85 in comparison to that of T cell
epitopes. B-cell epitope produces immune response
when it interacts with B lymphocytes. It then initiates
the differentiation of B lymphocytes into plasma and
memory cells (Nair et al. 2002). There are a number
of Web-based tools are available for the prediction of
B-cell epitope which are hosted by IEDB-AR. For the
B-cell epitope prediction with high accuracy, multiple
tools, including the Emini surface accessibility predic-
tion (Emini et al. 1985), Kolaskar and Tongaonkar
antigenicity scale (Kolaskar and Tongaonkar 1990),
Parker hydrophilicity prediction, (Parker et al. 1986)
and finally the Chou and Fasman beta turn prediction
tool (Chou and Fasman 1979) were employed, because
the antigenic parts of a protein belong to the beta turn
regions (Rini et al. 1992).
Homology modeling and protein variability determination
of the conserved region
The structure of the conserved region was constructed
by homology modelling using the MODELLER v9 (Šali
et al. 1995). MODELLER is a program that implements
an automated approach to comparative protein structure
modelling by satisfying spatial restraints (Fiser et al.
2000, Sali and Blundell 1993). Finally, the evaluation of
the predicted model was verified by using two software
tools, PROCHECK (Arnold et al. 2006, Laskowski et al.
1996) and QMEAN (Benkert et al. 2011). For predicting
the disorder among the amino acid sequences, DISOPRED
v3 (Ward et al. 2004) server was used. In order to calculate
the protein variability index the Protein variability server
was implied where Wu-Kabat variability coefficient
(Garcia-Boronat et al. 2008) has been used.
Allergenicity and epitope conservancy analysis
The web-based AllerHunter server (Muh et al. 2009)
was used to predict the allergenicity of our proposed
epitope for vaccine development. This server predicts
allergenicity through a combinational prediction, by
using both integration of the Food and Agriculture
Organization (FAO)/World Health Organization (WHO)
allergenicity evaluation scheme and support vector ma-
chines (SVM)-pairwise sequence similarity. AllerHunter
predicts allergens as well as nonallergens with high
specificity. This makes AllerHunter is a very useful
program for allergen cross-reactivity prediction (Liao
and Noble 2003).
Epitope conservancy of the candidate epitopes was ex-
amined using a Web-based epitope conservancy tool
available in IEDB analysis resource (Bui et al. 2007). The
conservancy level of each potential epitope was calcu-
lated by looking for identities in all RNA-dependent
RNA polymerase-L protein sequences of different strains
retrieved from database.
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Results
Analysis of the retrieved sequences with divergence
and antigenicity
A total of 52 RNA-dependent RNA polymerase-L protein
molecules from different variants of the EBOV were re-
trieved from the UniProt database. The MSA of the RNA-
dependent polymerase-L proteins was retrieved from
BioEdit tool through ClustalW with 1000 bootstrap repli-
cates (Additional file 1: Figure S1). CLC Sequence Viewer
was used to construct phylograms from the MSA obtained
from BioEdit, in order to analyze the divergence among
the retrieved sequences. Phylogram of RNA-dependent
RNA polymerase-L is depicted in Fig. 1. Finally, the highly
conserved region from the MSA was retrieved for the fur-
ther analysis. The selected conserved region is depicted in
the Fig. 2, from the MSA number 586 to 660. Then the
VaxiJen v2.0 server calculate the antigenicity of the con-
served sequences with a score 0.4888.
Fig. 1 Phylogenetic tree showing the evolutionary divergence among the different RNA-dependent RNA polymerase-L proteins of the EBOV.
Notes: Here, cladogram view is shown with appropriate distance among the different strains. The red dotted view indicates the node of the tree
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Fig. 2 MSA of the conserved region of RNA-dependent RNA polymerase-L. Only the conserved sequences containing the proposed epitope sequence
are shown here. Notes: Clustalx color is used here. Different colors indicate different amino acid residues. The yellow bas at the bottom indicates the
conservation of the amino acid residues
Table 1 Prediction of the T-cell epitope by NetCTL server on
the basis of combined score






Table 2 Prediction of the T-cell epitope by CTLPred server
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Identification of T-cell epitope and MHC interaction
analysis
T-cell epitopes were selected firstly by using the NetCTL
v1.2 server where the epitope prediction was confined to
12 MHC-I supertypes. Based on the combined score, the
top five epitopes (Table 1) were listed for further ana-
lysis. T-cell epitopes were again predicted by the
CTLPred server (Table 2). Here a combined approach of
artificial neural networks and support vector machines
was applied. Depending on the two analyses, the most
common epitope—containing peptides, identified by both
servers, was selected. The selected epitope was then used
for the MHC-binding analysis.
MHC-I-binding prediction, which was run through the
Stabilized Matrix Method, predicted a wide range of
MHC-I allele interactions for the proposed T-cell epi-
topes. The MHC-I alleles for which the epitope showed
higher affinity (IC50 < 250 nM) are listed in Table 3. The
output of the MHC-II interaction analysis is also shown
in Table 3.
Analysis of the population coverage
IEDB population coverage tool analyzed the Population
coverage of the proposed epitope. The combined MHC-I
and MHC-II class were assessed against the whole world
population with the selected MHC-I and MHC-II inter-
acted alleles (Fig. 3).
Prediction B-cell epitope
Here, for predicting potential B-cell epitopes, we used
amino acid–based methods. According to this procedure
different analysis methods were applied for the identifi-
cation of a continuous B cell epitope.
The Kolaskar and Tongaonkar antigenicity scale
was used for assessing the antigenic property of the
peptides. The average antigenic propensity of the
protein was 1.014, with a maximum of 1.033 and a
minimum of 1.002. For the protein the antigenic de-
termination threshold value was 1.0, where all values
equal or greater than 1.0 were potential antigenic
determinants. The antigenic plot is depicted in the
Fig. 4.
To be a potent B cell epitope, it must be surface ac-
cessible. Hence, Emini surface accessibility prediction
was employed, with a maximum propensity score of
1.297 at threshold 1.0 (Fig. 5). To strengthen our sup-
port for the prediction of the epitope to elicit B cell re-
sponse the Parker hydrophilicity and the Chou and
Fig. 3 Population coverage based on MHC–I and MHC-II restriction data. The whole world populations are assessed for the proposed epitope.
Notes: In the graphs, the line (−o-) represents the cumulative percentage of population coverage of the epitopes; the bars represent the population
coverage for each epitope
Table 3 MHC-I and MHC-II interaction of the proposed sequence by IEDB analysis resource
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Fasman beta turn prediction were employed. Those are
described in the Figs. 6 and 7.
Structure analysis and protein variability determination
Homology model of the conserved region was obtained
by the MODELLER software, which is shown in Fig. 8a
and b. PROCHECK server validated the stereochemical
quality of the model through Ramachandran Plot
(Fig. 8c), andQMEAN server also assessed the tertiary
structure, with a Qmean6 score of 0.327. DISOPRED v3
server predicted the disorder of the conserved peptide in
order to get insight about the disorder among the con-
served sequences, which is depicted in Fig. 9. Protein
variability server predicted the variability of the con-
served region of the RNA-dependent RNA polymerase-L
(Fig. 10) to ensure that the proposed epitope is within
the invariable region.
Epitope conservancy and allergenicity analysis
Conservation analyses of the proposed epitopes were an-
alyzed by the IEDB conservancy analysis tool that is
shown in Table 4. AllerHunter server predicted the
Fig. 4 Kolaskar and Tongaonkar antigenicity prediction of the proposed epitope. Notes: The X- and Y-axes represent the sequence position and
antigenic propensity score, respectively. The threshold value is 1.0. The regions above the threshold are antigenic, shown in yellow
Fig. 5 Emini surface accessibility prediction of the proposed epitope, with a minimum propensity score of 0.566 and maximum score of 1.297.
Notes: The X- and Y-axes represent the sequence position and surface probability, respectively. The threshold value is 1.0. The regions above the
threshold are antigenic, shown in yellow
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allergenicity of the queried epitope with a score was 0.03
(sensitivity =94.4. %, specificity =70.3 %).
Discussion
Our world is the habitation of more than seven billion
people now. With the upgrade of medical science, new
viruses along with their causing diseases are also emer-
ging. Ebola virus is such kinds of virus with a deadly out-
rage of their endemic nature especially in Africa in
recent time (Evans and Popova 2015). Till now there is
no potential treatment for this virus to combat its deadly
effects.
Recent time, the immunoinformatics approach give us
some sort of hope for the design of an effective thera-
peutics, like vaccine, in association with the advance-
ment of sequence based technology. Similar approaches
have been used successfully for identifying vaccine can-
didates in several pathogens viz. human corona virus
(Oany et al. 2008), Saint Louis encephalitis virus (Hasan
et al. 2013), Crimean–Congo hemorrhagic fever virus
Fig. 6 Parker hydrophilicity prediction of the epitope, with a minimum propensity score of −0.443 and maximum score of 1.471. Notes:
The X- and Y-axes represent the sequence position and antigenic propensity score, respectively. The threshold value is 1.0. The regions
above the threshold are antigenic, shown in yellow
Fig. 7 Chou and Fasman beta turn prediction of the epitope,with a minimum propensity score of 0.878 and maximum score of 0.939. Notes: The
X- and Y-axes represent the sequence position and antigenic propensity score, respectively. The threshold value is 1.0. The regions above the
threshold are antigenic, shown in yellow
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(Oany et al. 2015), Chikungunya virus (Hasan et al.
2015) and some others. The in vitro validation of this
type of work has also been proven in recent time (Khan
et al. 2014).
Though epitope-based vaccine designing has become a
familiar approach, in the case of EBOV no significant
work yet has been done. EBOV is an RNA virus which
has genetic blueprints made of RNA instead of DNA.
Creating vaccines is particularly difficult for RNA viruses
as they can quickly mutate their different exposed pro-
teins (Twiddy et al. 2003). Therefore the most potential
way to create stable antiviral therapies against RNA vi-
ruses including EBOV is to target the transcription or
replication machinery. Scientists revealed that RNA-
dependent RNA polymerase-L (EBOL) is an important
cellular component for the transcription and replication
of the EBOV genome. When an EBOV infects a cell,
its RNA genetic blueprint enters the cell along with
RNA-dependent RNA polymerase-L. This polymerase
normally “read” the RNA genetic blueprint in order to
synthesize mRNA, which then leads to the formation
of viral proteins as well as viral replication and more
viral particles are produced. For these two vital involve-
ments at the gateway, this protein was targeted to design
most potential epitopes using in silico computational
approaches.
Fig. 8 Three-dimensional model of the RNA-dependent RNA polymerase-L with the proposed epitope and validation. Notes: Two different view
of the modeled protein (Blue spherical) with the predicted epitope (Red spherical). a Top view. b Side view. The outerside location of the epitope
indicates its surface accessibility. c Ramachandran plot of the predicted model shows that most of the residues are in the allowed region of the
plot, proving the validity of the model
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In the current study, firstly all the available sequences
of RNA-dependent RNA polymerase-Lwere retrieved
from database. Then antigenicity of the conserved pep-
tides, generated by multiple sequence alignment was
predicted by VaxiJen, which suggested their ability to
elicit potential immune response. Sequence based bio-
informatics approaches were applied to predict both B
cell and T cell epitopes for conferring immunity in dif-
ferent ways. Though at present, most of the vaccines are
based on B cell immunity; vaccines based on T cell epi-
tope have been encouraged recently. It is because, with
time humoral response from memory B cells can be
overcome easily by antigenic drift, while cell mediated
immunity often provides long lasting immunity (Bacchetta
et al. 2005, Igietseme et al. 2004). Cytotoxic CD8+T
lymphocytes (CTL) inhibit the spread of infectious agents
by recognizing and killing infected cells or secreting
specific antiviral cytokines (Garcia et al. 1999, Shrestha
and Diamond 2004). Thus, vaccination based on T cell
epitope is a unique approach to obtain strong immune
response against infectious agents, such as, viruses
(Klein et al. 2005).
Both NetCTL and CTLPred server were used to find
epitopes for the activation of T-cell immunity with po-
tential antigenicity. By examining the output it was pre-
dicted that FRYEFTAPF would be the best epitope
candidate and was further subjected for binding profi-
ciency analysis.
Length is an important factor to consider for peptide
antigen binding with MHC or TCR or both. T cell epi-
topes presented by MHC class I molecules are generally
peptides between 8 and 11 amino acids in length. We
therefore set peptide lengths at 9 before making software
based MHC class I T cell epitope identification using
Fig. 10 Protein variability index of the conserved peptides of all the sequences. The prediction suggests that our proposed epitope “FRYEFTAPF”
falls in the invariable region (Blue line). Notes: The conservancy threshold was 1.0 in this analysis. The X-axis indicates the amino acid positions in
the sequences and the Y-axis indicates the Shannon variability score
Fig. 9 Disorder prediction of the conserved antigenic amino acid sequences. Here, our proposed epitope lies outside (56–64) of the disordered
region to secure its potentiality as an effective epitope. Notes: Amino acids in the input sequence are considered disordered when the blue line
is above the gray dashed line, that is, when the confidence score is 0.5. The orange line shows the confidence score of the disordered protein-binding
residue predictions
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immune epitope database (IEDB). Analysis revealed that
the core epitope “FRYEFTAPF” would interact with ten
different MHC class I alleles. On the other hand, the
complete peptide “NLAFRYEFTAPFIEY” interacts with
the highest numbers of MHC class II alleles (as many as
26 alleles).
Along with the T-cell epitope, in our study, attention
was also given to the B-cell epitope, which can induce
both primary and secondary humoral immunity (Trainor
et al. 2007). Multiple prediction methods were applied
to determine the B-cell epitope considering several cri-
teria of antigenicity, hydrophilicity, surface accessibility,
and beta-turn. Our proposed epitope has met all the cri-
teria of the above B-cell prediction methods.
The three-dimensional model of the conserved protein
ensured the exact location of the epitope outside of the
protein (Fig. 8a and b) surface and the model validity
was assessed by Ramachandran Plot (Fig. 8c), whereby
87.8 % amino acid residues were found within the fa-
vored region. The epitope was also treated as suitable
candidate for vaccine through tenabled its position in
the conserved sequence, by the Discopred and protein
variability server (Figs. 9 and 10).
Conservancy is the most important criterion of an epi-
tope to consider it for vaccine development. Conser-
vancy analysis of our proposed epitope showed 100 %
conservancy among all the available sequences. Another
important feature of the peptide vaccine is its allergen-
icity (McKeever et al. 2004). In silico analysis revealed
that the proposed epitope is nonallergenic in nature.
Wide range population coverage must be needed for a
potential vaccine aspirant. At this point, our proposed
epitope covers a remarkable population of 99.87 % for
both types of MHC allele throughout the world popula-
tion. That makes the epitope as a supreme candidate for
vaccine consideration.
Finally, from the above in silico analysis, we are really
optimistic that our proposed epitope would trigger an
immune response in vitro and in vivo.
Conclusion
A number of approaches exist for new vaccine develop-
ment, such as recombinant vaccines, sub-unit protein and
DNA vaccines, auxotrophic organisms to deliver genes and
so on. Current study is an attempt to identify potential epi-
tope targets against EBOV using different computational
tools. It is quite obvious that in order to minimize the
deadly effects of EBOV, highly potential drugs are immedi-
ately required and these in silico approaches will reduce
the wet lab efforts with higher probability of success.
Therefore, it is concluded that the identified epitope may
be exploited further for developing epitope-based vaccine
against EBOV. Nevertheless, the initial hints we obtained
will help to prioritize potential therapeutics for EBOV.
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